Patent information
IP India · live recordAbstract
The purpose of the invention is to provide a glucan containing at least one residue selected from an N-acetylglucosamine residue and a galactose residue, and a modified product thereof. A branched glucan according to the invention is a branched glucan in which at least one residue selected from an N-acetylglucosamine residue and a galactose residue is linked via an α-1,4-linkage to each of two or more non-reducing ends among a plurality of non-reducing ends of a branched α-1,4-glucan, and at positions other than the non-reducing ends of the branched α-1,4-glucan, either of an N-acetylglucosamine residue or a galactose residue is not present.
Applicants
1Inventors
5Specification
Show full textCollapse
DESCRIPTION TITLE OF THE INVENTION: NON-REDUCING END MODIFIED GLUCAN, METHOD FOR PRODUCING SAME, AND USE THEREOF 5 TECHNICAL FIELD
[0001] The present invention relates to a glucan in which at least one (preferably at least two) non-reducing end is modified, a modified product thereof, as well as a method 10 for producing the same, and utilization of the same. More preferably, the present invention relates to a glucan in which at least one residue selected from an N-acetylglucosamine residue and a galactose residue is bound via an -1,4-bond to each of at least one (preferably at 15 least two) non-reducing end, a modified product thereof, as well as a method for producing the same, and utilization of the same. BACKGROUND ART 20 [0002] A medically effective ingredient of medicaments is rapidly changing from a chemically synthesized stable low-molecular weight compound to an unstable substance which is easily degraded in blood, such as a protein, an antibody and a nucleic acid. For this reason, there is a necessity 25 of stabilizing these unstable medically effective ingredients to keep the blood concentration of the medically effective ingredient high for an elongated time. In addition, in order to decrease side effects of drugs, a necessity of delivering drugs to a target tissue efficiently has been 30 increasing. Under such a background, a so-called drug delivery system (DDS) technique has been utilized in earnest (Non-Patent Documents 1 to 4). A DDS technique refers to a technique and a system for allowing a medically effective EG038PCT ingredient to act on "a required site" at "a required amount" for "a required period of time", that is, controlling it with an ideal pharmacokinetics for a drug to maximally exert the effect. [5 0003] In the DDS technique, a modifying material for a medically effective ingredient is important. The term "modifying material for a medically effective ingredient" in the present specification refers to a material which modifies a medically effective ingredient by covalently 10 binding, or via non-covalent type interaction, with a medically effective ingredient. By utilizing the modifying material, a variety of properties (for example, pharmacokinetics (for example, absorption, distribution, metabolism and excretion), pharmacological effect, 15 stability and the like) of the medically effective ingredient can be modified. As a substance which has been used previously as the modifying material for the medically effective ingredient, there are a variety of substances, most generally it is a macromolecular material. For example, 20 polyethylene glycol (PEG) which is a synthetic macromolecule, and derivatives thereof are widely utilized as a modifying material for medically effective ingredients. Many medically effective ingredient-modifying materials having a functional group for binding the medically effective 25 ingredient on a terminus of a PEG chain have been developed, and such modifying materials are actually utilized in producing a medicament. Specific application examples include pegylated interferon (product name: PEGASYS). Since interferon has a small molecular weight and is easily 30 excreted into urine, there was a problem that it has a short half-life in blood. However, the half-life in blood was successfully enhanced dramatically by covalently binding interferon to a PEG chain having a molecular weight of EG038PCT 40,000 to form an interferon -conjugate having a high molecular weight. As described above, the remarkable effect is recognized in the modification of the medically effective ingredient or the nanoparticulate carrier for DDSs, with a 5 macromolecular material.
[0004] However, on the other hand, a problem has been pointed out. For example, when a high-molecular weight synthetic macromolecule which has no degradability in a living body and will not undergo renal glomerular filtration is 10 administered to blood, there is a risk that the macromolecule is accumulated in a particular organ and a risk that side effects due to the accumulation are generated. The reason is that a molecule having a molecular weight of a few tens thousands or less present in blood, undergoes renal 15 glomerular filtration and is rapidly excreted into urine, but a molecule having a molecular weight of a few tens thousands or more does not undergo renal glomerular filtration and its excretion into urine is limited. For this reason, a modifying material of the medically effective ingredient 20 which can be safely utilized is expected.
[0005] Polysaccharides have been used as a food raw material for a long time and, in recent years, have begun to be paid attention as a macromolecular material which is environment friendly, as a safe material having biocompatibility and, 25 further, as a functional material.
[0006] An -1,4 glucan, represented by a starch, glycogen or the like, is a safe natural material which is easily degraded in the environment and also in a body of a human, and is promising as a material in the industry of a DDS medicament, 30 regenerative medicine, intracorporeal imaging or the like, which is expected to grow in the future. When the -1,4 glucan is used for such a purpose, it is necessary to impart to the -1,4 glucan a function of interacting with a medically EG038PCT effective ingredient and a function of targeting to an organ and a tissue, and at the same time, it is necessary to control degradability of the -1,4 glucan.
[0007] On the other hand, in the pharmaceutical field, a vaccine for preventing or treating an infectious 5 disease, a cancer or the like is being developed. The vaccine is for administration of an antigen into a body and preventing or treating a disease utilizing an immune response to the antigen. Usually, as the antigen, in the case of a vaccine for an 10 infectious disease, a part of a pathogen, a whole inactivated pathogen, or a surface protein or a peptide of a pathogen is used. As the antigen, in the case of a cancer vaccine, a protein or a peptide which is specifically expressed on a cancer cell surface is used. Generally, since mere 15 administration of an antigen alone does not lead to effective immunity induction in many cases, a substance which induces an immune response (adjuvant) is administered into a body together with the antigen. For developing an effective vaccine, it is important to develop a safe and effective 20 adjuvant. It is expected an effective and safe adjuvant effectively functions when a purified protein or peptide is administered as an antigen.
[0008] In recent years, due to progress of natural science, a mechanism of immunological system has been revealed. It 25 has been revealed that a dendritic cell or a macrophage which is an antigen-presenting cell plays a central role of an immune reaction, and activation of an antigen-presenting cell and induction of production of an inflammatory cytokine (IL-2, IL-6, IL-12, TNF- and the like) that results from 30 the activation, are necessary for effective immunity induction. It has also been revealed that a substance which has been traditionally utilized as an adjuvant is involved in induction and enhancement of an immune reaction through EG038PCT stimulation and activation of an antigen-presenting cell, and induction of production of an inflammatory cytokine by Takehiko Sasazuki, Nankodo Co., Ltd.) (original book 5 Kenneth Murphy, Paul Travers, Mark Walport 2008 Garlnd Science, Taylar & ).
[0009] Conventionally, a variety of adjuvants are known, but there are few safe and low cost immune adjuvants which 10 can be used in tumor immunotherapy for the purpose of treating a human tumor, or preventing metastasis and reoccurrence of a human tumor. For example, in tumor immunotherapy utilizing a cultured dendritic cell, keyhole limpet hemocyanin is used as an immune adjuvant (Geiger, J. D., 15 et al., Cancer Res., 61, pp. 8513-8519, 2001), but keyhole limpet hemocyanin is expensive. A method of administering cytokines such as granulocyte-macrophage colony stimulating factor (sometimes -) which directly activates a dendritic cell as an immune adjuvant has been 20 proposed, but cytokines are further expensive.
[0010] In the production of a vaccine as a countermeasure for an infectious disease, as a safe and low cost immune adjuvant, immune adjuvants having insufficient immune adjuvant activity such as alum (aluminum hydroxide) and 25 toxicity is feared) are used. These are low in toxicity, but are weak in the immune adjuvant activity, as compared ed in an animal experiment. 30 [0011] As described above, the conventional adjuvant (also referred to as an immune adjuvant) has a problem in the ability to stimulate an immune response, safety or both of them. For this reason, it is very important to develop an adjuvant EG038PCT which has a high ability to stimulate an immune response, that is, the ability to stimulate an antigen-presenting cell, and is safe. 5 [Prior Art Documents]
Non-Patent Documents
[0012] [Non-Patent Document 1] Hiroaki Okada, "Drug delivery using functional DDS carriers" Chapter 1, General Statement: Kinousei DDS carrier wo mochiita seizai sekkei 10 ni yoru soyaku (Drug Discovery by Preparation Design Using Functional DDS Carrier), CMC Publishing Co., Ltd., 2008, 1-23 [Non-Patent Document 2] Masayuki Yokoyama, "Polymeric materials for drug carriers, Special Topic, DDS ni riyou 15 sareru kobunshi kagaku (Polymer Chemistry Utilized in DDS)", Drug Delivery System 23-6, 2008: 610-617 [Non-Patent Document 3] Maria Laura Immordino et al., International Journal of Nanomedicine 2006: 1(3) 297-315 [Non-Patent Document 4] J. Milton Harris and Robert B. Chess, 20 NATURE REVIEWS, DRUG DISCOVERY, VOLUME 2, MARCH 2003, 214-221 SUMMARY OF THE INVENTION PROBLEMS TO BE SOLVED BY THE INVENTION
[0013] The present invention is intended to solve the 25 above-mentioned problems.
[0014] An ideal modifying material for the medically effective ingredient which can be safely utilized is thought to have the following characteristics: (1) The modifying material shall be a macromolecular 30 material which can be degraded in a living body; (2) The modifying material shall have such a stable quality that it can be usable as a medicament. That is, the structure can be specified, and a modifying material having EG038PCT the same quality shall be able to produce every time; (3) The modifying material shall have a functional group which can bind to or interact with a medically effective ingredient; and (4) The modifying 5 material shall have tissue targeting functions or cell stimulation functions.
[0015] The present inventors thought that an excellent macromolecular substance for modifying material for the medically effective ingredient is a glucan (in the present 10 specification, the glucan refers to an -1,4-glucan, and an -1,4-glucan which is branched with an -1,6-bond(s)). Glycogen or a starch is accumulated in an animal's and plant's body as a polysaccharide for storage. Glycogen or a starch is one kind of glucan. Thus, glycogen or a starch which is 15 a component that is always present in a body of a human, and is excellent in biocompatibility. Further, the glucan undergoes hydrolysis by -amylase in a body, and is converted into glucose or a maltooligosaccharide being a component which is always present in a body. For this reason, the glucan 20 can be said to be the safest macromolecular material.
[0016] The glucan has another advantage that design of its structure is relatively easy. Methods for controlling the molecular weight, degree of branching, cyclization and the like of the glucan are known. Completely linear glucans in 25 which glucose residues are bound only with an -1,4-bond, glucans which are branched at high frequency by some glucose residues bound with an -1,6-bond, and the like are available. In a branched glucan, every time an -1,6-bond is increased by one, one new non-reducing end is generated. The number 30 of -1,6-bonds can be suitably adjusted as desired upon synthesis of a glucan molecule.
[0017] On the other hand, the greatest problem when the glucan is utilized as the modifying material (for example, EG038PCT a carrier, a vaccine adjuvant or the like) as a medically effective ingredient is that the glucan does not have a functional group which can bind to or interact with the medically effective ingredient. It is possible to introduce 5 a cationic or anionic functional group into a large number of hydroxyl groups or aldehyde group on a reducing end present in a glucan using a known chemical method.
[0018] Further, it is preferable that a carrier has the tissue targeting function, in terms of utilization of a glucan 10 as a carrier of a medically effective ingredient. As a means for realizing targeting to an organ and a tissue, a method of utilizing a saccharide recognizing mechanism by a receptor or a lectin on a cell surface has been proposed. A receptor or a lectin on a cell surface does not recognize glucose, 15 but recognizes a monosaccharide such as galactose or mannose. Therefore, in order to impart the tissue targeting function to a glucan, it is necessary to bind a monosaccharide having the targeting function, other than glucose, to a non-reducing end of the glucan. 20 [0019] In order to utilize a glucan as a vaccine adjuvant, it is preferable that the glucan has high stimulating activity on an antigen-presenting cell playing a central role in an immune response. The antigen-presenting cell (a dendritic cell, a macrophage, or the like) is not activated by a glucan 25 consisting only of glucose residues, but is activated by a monosaccharide such as galactose or mannose. Therefore, in order to impart the high cell stimulating activity to a glucan, it is necessary to bind a monosaccharide having a cell stimulating function to a non-reducing end of the 30 glucan. However, a method of binding a monosaccharide other than glucose via -1,4 bond to a non-reducing end of a branched glucan having at least two non-reducing ends has not been previously known. For example, in Nawaji et al., Carbohydr. EG038PCT Res., 2008, 343, 2692-2696, it is described that -D-glucosamine-1-phospate (GlcN-1-P) can be transferred to a maltooligosaccharide using potato-derived glucan phosphorylase. However, Nawaji et al. describe on page 2694, 5 right column, lines 3-5 that N-acetylglucosamine-1-phosphate (GlcNAc-1-P) is not recognized by phosphorylase. Recognition of a substrate by an enzyme is extremely strict, and it is a common knowledge of those skilled in the art that a normal substrate becomes 10 unrecognizable as a substrate in many cases when it is modified even if only a little. A normal substrate for glucan phosphorylase is glucose-1-phosphate, and analogues of the substrate which were known to be recognized by glucan phosphorylase were only -D-xylose-1-phosphate, 15 mannose-1-phosphate, glucosamine-1-phosphate, glucuronic acid-1-phosphate (GlcA-1-P) and N-formylglucosamine-1-phosphate (GlcNF-1-P). For this reason, it was thought that phosphorylase cannot be used in order to transfer GlcNAc-1-P or galactose-1-phosphate 20 (Gal-1-P) to a glucan. MEANS FOR SOLVING THE PROBLEMS
[0020] The present inventors intensively studied in order to solve the aforementioned problems and found that Aquifex 25 aeolicus VF5-derived-glucan phosphorylase can utilize as a substrate galactose-1-phosphate (Gal-1-P) and N-acetylglucosamine-1-phosphate (GlcNAc-1-P) which are not its original substrates, can catalyze a reaction that binds a galactose residue (Gal residue) or an N-acetylglucosamine 30 residue (GlcNAc residue) via -1,4 bond to a non-reducing end of a -1,4 glucan, and in spite of this, this enzyme can hardly catalyze the reverse reaction thereof, and completed the present invention based on this finding. In EG038PCT addition, the present inventors also found that potato-derived -glucan phosphorylase can use Gal-1-P as a substrate, and Thermococcus zilligii AN1-derived -glucan phosphorylase can use Gal-1-P and GlcNAc-1-P as a substrate. These 5 -glucan phosphorylases are enzymes which, when act on glucose-1-phosphate which is the original substrate, catalyze both a reaction wherein a glucose residue is transferred to a glucan receptor (glucan synthesizing reaction) and a reaction wherein the glucose on the 10 non-reducing end of a glucan is phosphorolysed to generate glucose-1-phosphate (glucan degrading reaction). However, surprisingly, when these enzyme use N-acetylglucosamine-1-phosphate or galactose-1-phosphate as a substrate, these enzymes catalyze the reaction wherein 15 the residue of these monosaccharides is transferred to a glucan receptor (glucan synthesizing reaction), but hardly catalyze the reaction wherein the residue of these monosaccharides bound on the non-reducing end of a glucan is phosphorolysed to generate 20 N-acetylglucosamine-1-phosphate or galactose -1-phosphate (glucan degrading reaction). While glucan degrading reaction again releases the bound monosaccharide residue, the present inventors found that in the method of the present invention, -glucan phosphorylase hardly catalyzes the 25 glucan degrading reaction. That is, the catalytic activity for the synthesizing reaction is much higher than the catalytic activity for the degradation reaction. Due to this characteristic, if a glucan has a plurality of non-reducing ends, -glucan phosphorylase can bind at least one residue 30 selected from N-acetylglucosamine residue and galactose residue, one by one, to the plurality of non-reducing ends of the glucan. By utilizing this characteristic of this enzyme, the non-reducing end-modified glucan of the present EG038PCT invention became producible for the first time. Especially, it could be obtained for the first time by utilizing this characteristic of this enzyme that a non-reducing end-modified glucan having high frequency of (for example, 50% or more) binding rate of N-acetylglucosamine residue5 s or galactose residues (for example, glucosamine residues) to the non-reducing ends, starting with a glucan having a large number of (for example, 5 or more) non-reducing ends. In addition, the present inventors found that when a Gal 10 residue or a GlcNAc residue is bound via -1,4 bond to a non-reducing end of an -1,4 glucan, glucoamylase resistance can be imparted to the -1,4 glucan. Further, the present inventors found that the non-reducing end-modified glucan of the present invention can be accumulated into a particular 15 tissue (e.g. liver) when it is administered into blood. The present inventors also found that the non-reducing end-modified glucan of the present invention has the activity of stimulating an antigen-presenting cell (e.g. a dendritic cell or a macrophage) to produce IL-6 (antigen-presenting 20 cell stimulating activity). In addition, the present inventors found that the non-reducing end-modified glucan of the present invention is excellent in biodegradability, and degradation of the non-reducing end-modified glucan in a living body can be controlled by modifying (e.g. 25 acetylating) a hydroxyl group of the non-reducing end-modified glucan of the present invention.
[0021] In the non-reducing end-modified branched -1,4 glucan (e.g. a branched -1,4 glucan in which at least one residue selected from an N-acetylglucosamine residue and 30 a galactose residue is bound via -1,4 bond to each of at least one (preferably at least two) non-reducing end(s)), or a hydroxyl group-modified product thereof, a non-reducing end-modified product thereof and a reducing end-modified EG038PCT product thereof of the present invention, when at least one kind of residue selected from a glucuronic acid residue, a mannose residue and a xylose residue is further bound to at least one or more non-reducing ends among the plurality of non-reducing ends, the antigen-5 -presenting cell stimulating activity of these glucans can be further improved.
[0022] In the present invention, since a saccharide (e.g. N-acetylglucosamine or galactose) residue is transferred 10 using -glucan phosphorylase (EC2.4.1.1), linkage of a saccharide residue to a glucan is an -1,4 bond. That is, a carbon atom at a 4-position of a glucosyl residue at a non-reducing end of a glucan, and a carbon atom at a 1-position of a saccharide (e.g. N-acetylglucosamine or galactose) 15 residue are -bound via an oxygen atom.
[0023] In the present specification, the glucan of the present invention in which at least one residue selected from an N-acetylglucosamine residue and a galactose residue is bound via -1,4 bond to each of at least one non-reducing 20 end of a glucan is also referred to as a -reducing end-.
[0024] A saccharide residue to be bound to a non-reducing end in the non-reducing end-modified glucan of the present invention may be a residue of a monosaccharide, or may be 25 a residue of an oligosaccharide. That is, the saccharide residue to be bound to a non-reducing end may be an N-acetylglucosamine residue or a galactose residue, or an oligosaccharide residue thereof. In the present specification, an oligosaccharide means a compound wherein 30 2 or more and 10 or less monosaccharides are bound. The degree of polymerization of saccharide residue bound to one non-reducing end of the non-reducing end-modified glucan of the present invention can be, for example, about 2 or EG038PCT more, about 3 or more, about 4 or more, about 5 or more or the like, and can be, for example, about 10 or less, about 9 or less, about 8 or less, about 7 or less, about 6 or less, about 5 or less, about 4 or less, about 3 or less, about 2 or less or the like. In 5 one embodiment, the saccharide residue bound to one non-reducing end of the non-reducing end-modified glucan of the present invention is residue of 2 sugars (that is, a dimer).
[0025] The introduction amount of galactose residues or 10 N-acetylglucosamine residues to a glucan can be controlled by the branching frequency of the glucan used and the frequency of introduction of these residues to a non-reducing end. When one wants to increase an amount of introduction of these residues into a glucan, using a glucan having a high branching 15 frequency and increasing the frequency of introduction of these residues to the non-reducing end. When one wants to decrease an amount of introduction of these residues into a glucan, using a glucan having a low branching frequency or decreasing the frequency of introduction of these residues 20 to the non-reducing end. The lower limit of the introduction amount of these residues to a glucan is the state wherein one of these residues is introduced per glucan molecule, which can be attained by introducing a galactose residue or an N-acetylglucosamine residue to the non-reducing end 25 of the glucan having no branching. In the case of a glucan which is highly branched, since non-reducing ends are distributed in an outermost layer of a glucan molecule, it is considered that introduced either of these residues are distributed in an outermost layer of a glucan molecule after 30 introduction of either of these residues, and this is ideal for interaction and binding with the medically effective ingredient. As described above, a glucan which has either of these residues selectively bound to a non-reducing end EG038PCT has a possibility of being an excellent modifying material for the medically effective ingredient.
[0026] For example, the present invention provides the following glucans and the like: 5 (Item 1) A glucan wherein the glucan has non-reducing ends and at least one residue selected from an N-acetylglucosamine residue and a galactose residue is bound via an -1,4-bond to each of at least one of the non-reducing ends of the glucan 10 (preferably two or more of the two or more non-reducing ends), but neither an N-acetylglucosamine residue nor a galactose residue is present at the position other than the non-reducing ends of the glucan, wherein the glucan is a branched -1,4 glucan or a linear -1,4 glucan, and the degree of 15 polymerization of the branched -1,4 glucan or the linear -1,4 glucan is preferably 15 or more and 4 x 105 or less. It is noted that the glucan which has an N-acetylglucosamine residue or a galactose residue bound thereto of the present invention is also referred to as the non-reducing 20 end-modified glucan of the present invention. (Item 2) The glucan according to item 1, wherein the glucan is a branched -1,4-glucan, wherein the branched -1,4-glucan has a plurality of non-reducing ends and at least one residue 25 selected from an N-acetylglucosamine residue and a galactose residue is bound to each of at least one (preferably two or more) non-reducing ends of the branched -1,4-glucan. That is, this glucan is a branched -1,4-glucan wherein the branched -1,4-glucan has a plurality of non-reducing ends 30 and at least one residue selected from an N-acetylglucosamine residue and a galactose residue is bound via an -1,4-bond to each of at least one (preferably two or more) non-reducing ends of the branched -1,4-glucan, but neither an EG038PCT N-acetylglucosamine residue nor a galactose residue is present at the position other than the non-reducing ends of the branched -1,4-glucan, and the degree of polymerization of the branched -1,4 glucan is preferably 15 5 or more and 4 x 105 or less. (Item 3) The glucan according to item 2, wherein the branched -1,4-glucan is selected from the group consisting of a branched maltooligosaccharide, starch, amylopectin, 10 glycogen, dextrin, enzymatically synthesized branched glucan and highly branched cyclic glucan. (Item 4) A hydroxyl group-modified product of the glucan (non-reducing end-modified glucan) according to any one of items 1 to 3, 15 wherein the modification on the hydroxyl group is a modification on some or all of alcoholic hydroxyl groups of the glucan, and the modification on the hydroxyl group is independently selected from the group consisting of hydroxyalkylation, alkylation, acetylation, 20 carboxymethylation, sulfation and phosphorylation. (Item 5) A reducing end-modified product of the glucan (non-reducing end-modified glucan) according to any one of items 1 to 3 or a hydroxyl group-modified product thereof. 25 (Item 6) A non-reducing end-modified product of the glucan (non-reducing end-modified glucan) according to any one of items 2 to 3 or a hydroxyl group-modified product thereof, or a reducing end-modified product thereof, which is further 30 modified by liking a monosaccharide residue other than an N-acetylglucosamine residue and a galactose residue via an -1,4-bond to at least one non-reducing end of the plurality of non-reducing ends of the branched -1,4 glucan. EG038PCT (Item 6B) The non-reducing end-modified product of the glucan (non-reducing end-modified glucan) or a hydroxyl group-modified product thereof, or a reducing end-modified product thereof according to 5 item 6, wherein the monosaccharide residue is one kind or two kinds selected from a glucuronic acid residue, a glucosamine residue, a mannose residue, and a xylose residue. (Item 6C) 10 The non-reducing end-modified product of the glucan (non-reducing end-modified glucan) or a hydroxyl group-modified product thereof, or a reducing end-modified product thereof according to item 6, wherein the monosaccharide residue is one kind or two kinds selected 15 from a glucuronic acid residue and a mannose residue. (Item 7) A method for producing a glucan (that is, a non-reducing end-modified glucan of the present invention) in which at least one residue selected from an N-acetylglucosamine 20 residue and a galactose residue is bound to each of two or more non-reducing ends, characterized by allowing an -glucan phosphorylase to act on an aqueous solution comprising a glucan (preferably a branched -1,4-glucan having two or more non-reducing ends) and 25 N-acetylglucosamine-1-phosphate or galactose-1-phosphate, wherein the degree of polymerization of the glucan used as raw material is preferably 15 or more and 4 x 105 or less. (Item 8) The method according to item 7, wherein the -glucan 30 phosphorylase has 95% or more sequence identity with the amino acid sequence of -glucan phosphorylase derived from Aquifex aeolicus VF5, and has activity of transferring N-acetylglucosamine residue or galactose residue to a EG038PCT non-reducing end of a glucan to form an -1,4-bond. (Item 9) A medicament comprising: the glucan comprising an N-acetylglucosamine residue 5 or a galactose residue according to any one of items 1 to 3, a hydroxyl group-modified product thereof, or a reducing end-modified product thereof, and a medically effective ingredient. (Item 10) 10 A medicament comprising: a non-reducing end-modified product of the glucan comprising an N-acetylglucosamine residue or a galactose residue according to any one of items 2 to 3 or a hydroxyl group-modified product thereof, or a reducing end-modified 15 product thereof, which is further modified by liking a monosaccharide residue other than an N-acetylglucosamine residue and a galactose residue via an -1,4-bond to at least one non-reducing end of the plurality of non-reducing ends of the branched -1,4 glucan, wherein the monosaccharide 20 residue is one kind or two kinds selected from a glucuronic acid residue, a glucosamine, a mannose residue, and a xylose residue; and a medically effective ingredient. (Item 11) 25 The medicament according to item 9 or 10, wherein the medically effective ingredient is selected from the group consisting of a low-molecular weight organic compound, a protein, a peptide, an antibody, an antibody fragment, a receptor, a receptor fragment, a DNA, an RNA, a siRNA, an miRNA and an 30 RNA aptamer. (Item 11A) The medicament according to any one of items 9 to 11, wherein the medically effective ingredient is an antigen protein EG038PCT or a peptide. (Item 12) A composition for clinical diagnosis comprising the glucan comprising an N-acetylglucosamine residue or a galactose residue according to any one of items 5 ems 1 to 3, a hydroxyl group-modified product thereof, or a reducing end-modified product thereof. (Item 13) A composition for clinical diagnosis comprising a 10 non-reducing end-modified product of the glucan comprising an N-acetylglucosamine residue or a galactose residue according to any one of items 2 to 3 or a hydroxyl group-modified product thereof, or a reducing end-modified product thereof, which is further modified by liking a 15 monosaccharide residue other than an N-acetylglucosamine residue and a galactose residue via an -1,4-bond to at least one non-reducing end of the plurality of non-reducing ends of the branched -1,4 glucan, wherein the monosaccharide residue is one kind or two kinds selected from the group 20 consisting of a glucuronic acid residue, a glucosamine, a mannose residue, and a xylose residue. (Item 14) A nanoparticulate carrier for a DDS comprising the glucan comprising an N-acetylglucosamine residue or a galactose 25 residue according to any one of items 1 to 3, a hydroxyl group-modified product thereof, or a reducing end-modified product thereof. (Item 15) A nanoparticulate carrier for a DDS comprising a non-reducing 30 end-modified product of the glucan comprising an N-acetylglucosamine residue or a galactose residue according to any one of items 2 to 3 or a hydroxyl group-modified product thereof, or a reducing end-modified product thereof, which EG038PCT is further modified by liking a monosaccharide residue other than an N-acetylglucosamine residue and a galactose residue via an -1,4-bond to at least one non-reducing end of the plurality of non-reducing ends of the branched -1,4 glucan, wherein the monosaccharide 5 accharide residue is one kind or two kinds selected from the group consisting of a glucuronic acid residue, a glucosamine, a mannose residue, and a xylose residue. (Item 16) 10 The carrier according to item 14 or 15, wherein the nanoparticulate carrier for a DDS is selected from the group consisting of a liposome, a virus particle, a macromolecule micelle and a nanogel composed of macromolecule bearing hydrophobic groups. 15 (Item 17) A vaccine adjuvant comprising the glucan comprising an N-acetylglucosamine residue or a galactose residue according to any one of items 1 to 3, a hydroxyl group-modified product thereof, or a reducing end-modified product thereof. 20 (Item 18) The vaccine adjuvant according to item 17, further modified by liking a monosaccharide residue other than an N-acetylglucosamine residue and a galactose residue via an -1,4-bond to at least one or more non-reducing end of the 25 plurality of non-reducing ends of the branched -1,4 glucan, wherein the monosaccharide residue is one kind or two kinds selected from a glucuronic acid residue and a mannose residue. EFFECTS OF THE INVENTION 30 [0027] It is thought that the non-reducing end-modified glucan (a glucan in which at least one residue selected from an N-acetylglucosamine residue and a galactose residue is bound via an -1,4 bond to each of at least one (preferably EG038PCT at least two) non-reducing end(s)), a hydroxyl group-modified product thereof, a non-reducing end-modified product thereof and a reducing end-modified product thereof of the present invention can be accumulated into a particular tissue when administered into blood. Since the non-5 -reducing end-modified branched -1,4 glucan (a branched -1,4 glucan in which at least one residue selected from an N-acetylglucosamine residue and a galactose residue is bound via an -1,4 bond to each of at least one (preferably at 10 least two) non-reducing end(s)), a hydroxyl group-modified product thereof, a non-reducing end-modified product thereof and a reducing end-modified product thereof of the present invention have the activity of stimulating an antigen-presenting cell such as a dendritic cell or a 15 macrophage to produce IL-6 (antigen-presenting cell stimulating activity), they are thought to be usable as a vaccine adjuvant. In the non-reducing end-modified branched -1,4 glucan (a branched -1,4 glucan in which at least one residue selected from an N-acetylglucosamine 20 residue and a galactose residue is bound via an -1,4 bond to each of at least one (preferably at least two) non-reducing end(s)), a hydroxyl group-modified product thereof, a non-reducing end-modified product thereof and a reducing end-modified product thereof of the present invention, when 25 at least one kind of residue among a glucuronic acid residue, a mannose residue and a xylose residue is further bound to at least one or more non-reducing ends among the plurality of non-reducing ends, the antigen-presenting cell stimulating activity of these glucans can be further 30 improved. The non-reducing end-modified glucan, a hydroxyl group-modified product thereof, a non-reducing end-modified product thereof and a reducing end-modified product thereof EG038PCT of the present invention can have extended blood half life longer than that of an unmodified glucan, and are very safe since they are finally completely degraded in a living body and excreted. For this reason, these glucans and modified products thereof of the present invention 5 vention are useful as a modifying material for a medically effective ingredient, a clinical diagnostic, an imaging agent and a nanoparticulate carrier for DDS. Since the non-reducing end-modified glucan, a hydroxyl group-modified product thereof, a non-reducing 10 end-modified product thereof and a reducing end-modified product thereof of the present invention can be controlled in their structure by an enzymatic reaction, they are also excellent in quality stability. 15 BRIEF DESCRIPTION OF THE DRAWINGS
[0028] [Fig. 1] Fig. 1 shows the results of HPAEC-PAD analysis after digestion of a non-reducing end-modified branched glucan (B-GlcNAc) or an unmodified branched glucan (B) with various amylases. See Example 11. 20 [Fig. 2] Fig. 2 shows the results of HPAEC-PAD analysis after digestion of a non-reducing end-modified branched glucan (B-Gal) or an unmodified branched glucan (B) with various amylases. See Example 12. [Fig. 3] Fig. 3 shows a schematic view of a structure of 25 products which are thought to be obtained when a non-reducing end-modified branched glucan or an unmodified branched glucan (B) is degraded with various amylases. See Example 12. [Fig. 4] Fig. 4 is a graph showing a change in weight average molecular weight of a product over time when a branched glucan 30 which has an N-acetylglucosamine residue bound thereto is degraded with -amylase. See Example 13. [Fig. 5] Fig. 5 is a graph showing a change in weight average molecular weight over time when non-reducing end EG038PCT N-acetylglucosamine residue-bound branched glucans having different acetylation degrees are degraded with -amylase. See Example 14. [Fig. 6] Fig. 6 is a graph showing a change in weight average molecular weight of a product over time when a 5 branched glucan which has a galactose residue bound thereto is degraded with -amylase. See Example 15. [Fig. 7] Fig. 7 is a graph showing a change in weight average molecular weight over time when non-reducing end galactose 10 residue-bound branched glucans having different acetylation degrees are degraded with -amylase. See Example 16. [Fig. 8] Fig. 8 is a graph showing glucan residual ratios of an acetylated branched glucan which has N-acetylglucosamine residues bound to non-reducing ends and 15 an acetylated non-reducing end-unmodified-branched glucan (B) in blood. See Example 17. [Fig. 9] Fig. 9 is a graph showing glucan residual ratios of an acetylated branched glucan which has galactose residues bound to non-reducing ends and an acetylated non-reducing 20 end-unmodified-branched glucan (B) in blood. See Example 18. [Fig. 10] Fig. 10 is a graph showing concentrations of an acetylated branched glucan which has a galactose residue bound to a non-reducing end and an acetylated non-reducing 25 end unmodified branched glucan (B) in blood and liver. See Example 19. [Fig. 11] Fig. 11 is a graph showing an IL-6 production amount when various non-reducing end-modified glucans are contacted with a dendritic cell. See Example 20. 30 [Fig. 12] Fig. 12 is a graph showing an IL-6 production amount when various non-reducing end-modified glucans are contacted with a dendritic cell. See Example 22. [Fig. 13] Fig. 13 is a graph showing an IL-6 production amount EG038PCT when various non-reducing end-modified glucans are contacted with a dendritic cell. See Example 23. [Fig. 14] Fig. 14 is a graph showing an IL-6 production amount when various non-reducing end-modified glucans are contacted with a dendritic cell. See 5 Example 24. [Fig. 15] Fig. 15 is a graph showing an IL-6 production amount when various non-reducing end-modified glucans are contacted with a macrophage. See Example 25. [Fig. 16] Fig. 16 is a graph showing an IL-6 production amount 10 when various non-reducing end-modified glucans are contacted with a macrophage. See Example 26. MODE FOR CARRYING THE INVENTION
[0029] The present invention will be explained in detail 15 below.
[0030] Throughout the present specification, it should be understood that expression in a singular form includes a concept of a plural form thereof, unless otherwise indicated. In addition, it should be understood that a term used in 20 the present specification is used in a sense which is usually used in the art, unless otherwise indicated.
[0031] (1. Materials) (1.1) Glucans and modified products of glucan "Glucan", when used in the present specification, is a 25 polysaccharide having D-glucose as a constituent unit. In the present invention, it is preferable to use, as the glucan, an -D-glucan. The bonds which link glucose residues in an -D-glucan predominantly consist of an -1,4-glucosidic bond, and can contain an -1,6-glucosidic bond. An -D-glucan 30 containing a -1,6-glucosidic bond has a branched structure. A glucan having at least one -1,6-glucosidic bond in the molecule is referred to as a branched glucan, and a glucan having no -1,6-glucosidic bond in the molecule is referred EG038PCT to as a linear glucan. Preferable glucans used in the present invention are a linear glucan and a branched glucan, more preferably a linear -1,4-glucan and an -1,4-glucan which is branched with an -1,6-bond (also referred to as a branched -1,4 glucan). It is preferable that the glucan used in 5 the present invention does not contain an -1,3-bond.
[0032] The linear -D-1,4-glucan refers to a polysaccharide in which two or more saccharide units of D-glucose units are bound only with an -1,4-glucosidic bond(s). In the 10 present specification, unless otherwise indicated, the linear -D-1,4-glucan is referred to as a linear glucan or a linear -1,4-glucan. The linear glucan has one non-reducing end. Examples of the linear glucan suitably utilized in the present invention include 15 maltooligosaccharide and amylose.
[0033] In the present specification, the term "maltooligosaccharide" refers to a substance which is produced by dehydration condensation of about 2 to about 10 D-glucoses, wherein D-glucose units are bound by -1,4 20 bond(s). The degree of polymerization of a maltooligosaccharide is preferably about 3 or more, more preferably about 4 or more, and further preferably about 5 or more. The degree of polymerization of a maltooligosaccharide may be, for example, about 10 or less, 25 about 9 or less, about 8 or less, about 7 or less, or the like. Examples of maltooligosaccharides include maltooligosaccharides such as maltose, maltotriose, maltotetraose, maltopentaose, maltohexaose, maltoheptaose, maltooctaose, maltononaose, and maltodecaose. 30 [0034] In the present specification, the term "amylose" refers to a linear molecule constructed of glucose units connected via -1,4-bonds. An amylose is contained in natural starch. Amylose may be a natural amylose extracted EG038PCT from a natural starch, or may be an amylose synthesized by an enzymatic reaction (also referred to as "enzymatically synthesized amylose" in the present specification). Natural amylose may contain a branched part in some cases, 5 but enzymatically synthesized amylose does not contain a branch. Further, natural amyloses have a large polydispersity and has a variation in the molecular weight, but an enzymatically synthesized amylose (particularly, an enzymatically synthesized amylose synthesized by the SP-GP 10 method described in International Publication WO 02/097107 pamphlet) has a small polydispersity and has an extremely uniform molecular weight. For this reason, in the present invention, it is preferable to use an enzymatically synthesized amylose. The degree of polymerization of the 15 amylose used in the present invention is preferably about 2 or more, more preferably about 3 or more, still more preferably about 10 or more, and most preferably about 30 or more. The degree of polymerization of the amylose used in the present invention is preferably about 2 x 103 or less, more preferably about 1 x 103 20 or less, still more preferably about 700 or less and most preferably about 500 or less.
[0035] In the present specification, the term "branched -D-glucan" refers to a glucan in which a linear glucan, in which D-glucose units are connected with an 25 -1,4-glucosidic bond(s), is branched with a bond other than an -1,4-glucosidic bond. In the present specification, unless otherwise indicated, the branched -D-glucan is referred to as a branched glucan. A branching bond is either an -1,6-glucosidic bond, an -1,3-glucosidic bond, or an 30 -1,2-glucosidic bond, and most preferably is an -1,6-glucosidic bond. It is preferable that a branched -D-glucan used in the present invention does not contain an -1,3-glucosidic bond and an -1,2-glucosidic bond. The EG038PCT branched glucan usually has the same number of non-reducing ends as the number of branching bonds. When the branched glucan is treated with an enzyme which selectively breaks only an -1,6-glucosidic bond (for example, isoamylase, pullulanase, or the like), the branched glucan can be de5 graded into a mixture of linear -1,4-glucans. These are referred to as a unit chain of the branched glucan, and the degree of polymerization thereof is referred to as a unit chain length. 10 [0036] Examples of the branched glucan suitably utilized in the present invention include branched -1,4-glucans having 2 or more non-reducing ends, branched maltooligosaccharide, starches, amylopectin, glycogen, dextrin, enzymatically synthesized branched glucan and 15 highly branched cyclic glucan. Branched CD having one non-reducing end is not preferable.
[0037] In the present specification, the term "branched maltooligosaccharide" refers to a substance generated by dehydration condensation of about 3 to about 10 D-glucoses, 20 in which D-glucose units are bound mainly with an -1,4 bond(s), and which contains one or more branching bonds, i.e., 2 or more non-reducing ends. The degree of polymerization of the branched maltooligosaccharide is preferably about 4 or more, more preferably about 5 or more, further preferably about 25 6 or more. The degree of polymerization of the branched maltooligosaccharide may be, for example, about 10 or less, about 9 or less, about 8 or less, about 7 or less, or the like.
[0038] In the present specification, the term "starch" is 30 a mixture of amylose and amylopectin. As a starch, any starch can be used as long as it is commonly commercially available. The ratio of the amylose and amylopectin contained in a starch is different depending on the kind of plant producing the EG038PCT starch. Almost all starches possessed by glutinous rice, glutinous corn and the like are an amylopectin. On the other hand, a starch consisting only of amyloses, containing no amylopectin, can not be obtained from a common plant. Starch 5 is classified into natural starch, a degraded starch and modified starch.
[0039] Natural starch is classified into tuber starch and cereal starch depending on the raw material. Examples of tuber starches include potato starch, tapioca starch, sweet 10 potato starch, kudzu starch, bracken starch and the like. Examples of cereal starches include corn starch, wheat starch, rice starch and the like. Examples of natural starches are high amylose starches (for example, high amylose corn starch) or waxy starches. The starch can be a soluble starch. A 15 soluble starch refers to a water-soluble starch obtained by subjecting a variety of treatment on natural starch. The starch may be selected from the group consisting of soluble starch, waxy starch and high amylose starch. The starch may be a modified starch. 20 [0040] The degree of polymerization of the starch used in the present invention is preferably about 1 x 103 or more, more preferably about 5 x 103 or more, still more preferably about 1 x 104 or more, and most preferably about 2 x 104 or more. The degree of polymerization of the starch used in the present invention is preferably about 1 x 107 25 or less, more preferably about 3 x 106 or less, still more preferably about 1 x 106 or less and most preferably about 3 x 105 or less.
[0041] An amylopectin is a branched molecule in which a 30 glucose unit(s) is bound via an -1,6 bond to glucose units which are bound via an -1,4 bond(s). An amylopectin is contained in natural starch. As an amylopectin, for example, waxy corn starch, which consists of 100% amylopectin, can EG038PCT be used. The degree of polymerization of the amylopectin used in the present invention is preferably about 1 x 103 or more, more preferably about 5 x 103 or more, still more preferably about 1 x 104 or more, and most preferably about 2 x 104 or more. The degree of polymerization 5 of the amylopectin used in the present invention is preferably about 1 x 107 or less, more preferably about 3 x 106 or less, still more preferably about 1 x 106 or less and most preferably about 3 x 105 or less. 10 [0042] A glycogen is one kind of glucan constructed of glucose, and is a glucan having a high frequency of branching. A glycogen is widely distributed as a storage polysaccharide for animals in almost all cells in the granule state. In a plant, glycogen is present, for example, in the seed of 15 sweet corn species of corn. In a glycogen, typically, sugar chains consisting of glucoses bound via an -1,4-bond(s) which have an average degree of polymerization of 12 to 18 are bound by an -1,6-bond(s) at a ratio of around one chain every about 3 units of glucose, to a sugar chain consisting 20 of glucoses bound via an -1,4-bond(s). In addition, similarly, a sugar chain consisting of glucoses bound by an -1,4-bond(s) is bound by an -1,6-bond to a branch chain bound by an -1,6-bond(s). For this reason, glycogen forms a network structure. It is also possible to enzymatically 25 synthesize a glycogen. The degree of polymerization of the glycogen used in the present invention is preferably about 500 or more, more preferably about 1 x 103 or more, still more preferably about 2 x 103 or more, and most preferably about 3 x 103 or more. The degree of polymerization of the 30 glycogen used in the present invention is preferably about 1 x 107 or less, more preferably about 3 x 106 or less, still more preferably about 1 x 106 or less and most preferably about 3 x 105 or less. EG038PCT
[0043] Dextrin is one kind of glucan constructed of glucose, and is a glucan having a medium complexity between those of starch and those of maltose. Dextrin is obtained by partially degrading starch by an acid, an alkyl or an enzyme. Dextrin is also obtained 5 tained by partially degrading starch with a physical treatment such as sonication. The degree of polymerization of the dextrin used in the present invention is preferably about 10 or more, more preferably about 20 or more, still more preferably about 30 or more, and most 10 preferably about 50 or more. The degree of polymerization of the dextrin used in the present invention is preferably about 1 x 104 or less, more preferably about 9 x 103 or less, still more preferably about 7 x 103 or less and most preferably about 5 x 103 or less. 15 [0044] The enzymatically synthesized branched glucan refers to a branched glucan synthesized using an enzyme. By adding a branching enzyme to the reaction solution upon synthesis of amylose by the SP-GP method, the product can be branched. The extent of branching can be regulated by 20 the added amount of the branching enzyme. Since the enzymatically synthesized branched glucan has a uniform structure as compared with a natural branched glucan, it is very advantageous when used as a pharmaceutical material. For example, the degree of polymerization of the 25 enzymatically synthesized branched glucan used in the present invention is preferably about 15 or more, preferably about 20 or more, more preferably about 50 or more, still more preferably about 100 or more, and most preferably about 200 or more. The degree of polymerization of the enzymatically 30 synthesized branched glucan used in the present invention is preferably about 4 x 105 or less, preferably about 2 x 105 or less, more preferably about 1 x 105 or less, still more preferably about 5 x 104 or less and most preferably EG038PCT about 3 x 104 or less.
[0045] In the present specification, the term "highly branched cyclic glucan" refers to a glucan having an internally branched cyclic structural moiety and an externally branched structural moiety and having 5 a degree of polymerization of 50 or more. The highly branched cyclic glucan may have at least two non-reducing ends as a whole molecule. The degree of polymerization of the highly branched cyclic glucan as a whole molecule that can be used 10 in the present invention is preferably about 50 or more, more preferably about 60 or more, and still more preferably about 100 or more. The degree of polymerization of the highly branched cyclic glucan as a whole molecule that can be used in the present invention is preferably about 1 x 105 or less, more preferably about 7 x 104 15 or less, and still more preferably about 5 x 104 or less. The degree of polymerization of the highly branched cyclic glucan as a whole molecule that can be used in the present invention may be, for example, about 1 x 104 or less, about 7 x 103 or less, or about 5 x 103 or less. 20
[0046] The degree of polymerization of the internally branched cyclic structural moiety present in the highly branched cyclic glucan is preferably about 10 or more, more preferably about 15 or more, and further preferably about 25 20 or more. The degree of polymerization of the internally branched cyclic structural moiety present in the highly branched cyclic glucan is preferably about 500 or less, more preferably about 300 or less, and further preferably about 100 or less. 30 [0047] The degree of polymerization of the externally branched structural moiety present in the highly branched cyclic glucan is preferably about 40 or more, more preferably about 100 or more, further preferably about 300 or more, EG038PCT and further more preferably about 500 or more. The degree of polymerization of the externally branched structural moiety present in the highly branched cyclic glucan is preferably about 3 x 103 or less, more preferably about 1 x 103 or less, further preferably about 500 or less, and 5 further more preferably about 300 or less.
[0048] The number of -1,6-glucosidic bonds in the internally branched cyclic structural moiety present in the highly branched cyclic glucan may be at least one, and for 10 example, can be one or more, 5 or more, 10 or more or the like; the number of -1,6-glucosidic bonds in the internally branched cyclic structural moiety can be, for example, about 200 or less, about 50 or less, about 30 or less, about 15 or less, about 10 or less or the like. 15 It is preferable that the highly branched cyclic glucan used in the present application is a highly branched cyclic glucan in which the number of non-reducing ends in the externally branched structural moiety is 2 or more. The number of non-reducing ends (that is, "the number of 20 -1,6-glucosidic bonds" + 1) in the externally branched structural moiety present in the highly branched cyclic glucan is preferably about 2 or more, more preferably about 3 or more, further preferably about 4 or more, especially preferably about 5 or more, and most preferably about 10 25 or more. The number of non-reducing ends in the externally branched structural moiety present in the highly branched cyclic glucan is preferably about 5 x 103 or less, more preferably about 4 x 103 or less, and further preferably about 3 x 103 or less. 30 [0049] As the highly branched cyclic glucan, a highly branched cyclic glucan having one kind of a degree of polymerization may be used alone, or a mixture of highly branched cyclic glucans having a variety of degree of EG038PCT polymerization may be used. Preferably, the degrees of polymerization of the highly branched cyclic glucan is such that the ratio of the degrees of polymerization of the maximum degree of polymerization to the minimum degree of 5 polymerization is about 100 or less, more preferably about 50 or less, and further more preferably about 10 or less.
[0050] The highly branched cyclic glucan is preferably a glucan having an internally branched cyclic structural moiety and an externally branched structural moiety and having a degree of polymerization in a range of 50 to 5 x 10410 , wherein the internally branched cyclic structural moiety is a cyclic structural moiety formed with an -1,4-glucosidic bond and an -1,6-glucosidic bond, and the externally branched structural moiety is a non-cyclic structural moiety bound 15 to the internally branched cyclic structural moiety. The degree of polymerization of each unit chain of this externally branched structural moiety is, on average, preferably about 10 or more and preferably about 20 or less. The highly branched cyclic glucan and a method for producing the same 20 are described in detail in Japanese Laid-Open Publication No. 8-134104 (Japanese Patent No. 3107358), and this glucan can be produced according to the description of it. The highly branched cyclic glucan is commercially available, for example, as "Cluster Dextrin" from Ezaki Glico Co., Ltd. 25 The degree of polymerization of the highly branched cyclic glucan used in the present invention is preferably about 50 or more, more preferably about 70 or more, further preferably about 100 or more, most preferably about 150 or more. The degree of polymerization of the highly branched 30 cyclic glucan used in the present invention is preferably about 1 x 104 or less, more preferably about 7 x 103 or less, further preferably about 5 x 103 or less, and most preferably about 4 x 103 or less. EG038PCT
[0051] In a specific embodiment, the branched glucan can be particulate. It is known that particles having a diameter of about 4 nm or less are excreted from kidney, particles having a diameter of about 4 nm to about 200 nm are circulated in blood for a long 5 ng time, particles having a diameter of about 200 nm to about 7 m are captured by a reticuloendothelial system, and particles having a diameter of about 7 m or more obstruct capillary blood vessels. A reticuloendothelial system is distributed in liver and spleen. 10 For this reason, by controlling the particle size of the branched glucan, the pharmacokinetics of the non-reducing end-modified glucan and a modified product thereof of the present invention in vivo can be controlled. When one intends to circulate the particles in blood for a long time, the 15 particle size of a particulate branched glucan is, as the diameter, preferably about 4 nm or more, more preferably about 10 nm or more, preferably about 200 nm or less, and more preferably about 100 nm or less. The molecular weight of the particulate branched glucan having such a particle size is preferably about 5 x 105 20 or more, more preferably about 1 x 106 or more, preferably about 5 x 107 or less, and more preferably about 2 x 107 or less. For example, since it is known that particles having a diameter of 20 to 50 nm are accumulated in cancer cells, when it is intended that 25 the particles are accumulated in cancer cells, the particle size of the particulate branched glucan is, as the diameter, preferably about 10 nm or more, more preferably about 15 nm or more, preferably about 100 nm or less, and more preferably about 50 nm or less. The molecular weight of the particulate 30 branched glucan having such a particle size is preferably about 5 x 105 or more, more preferably about 1 x 106 or more, preferably about 2 x 107 or less, and more preferably about 5 x 106 or less. EG038PCT
[0052] The number of branches in the -glucan (i.e. the number of -1,6-glucosidic bonds) is preferably about 1 or more, more preferably about 2 or more, further preferably about 5 or more, and most preferably about 10 or more. The number of branches in the -glucan may be about 30 or 5 more. The number of branches of the -glucan (i.e. the number of -1,6-glucosidic bonds) is preferably about 5 x 103 or less, more preferably about 3 x 103 or less, further preferably about 2 x 103 or less. The number of branches in the -glucan may be about 1 x 103 10 or less.
[0053] In the branched -glucan used in the present invention, the ratio of the number of -1,6-glucosidic bonds relative to the number of -1,4-glucosidic bonds ("number of -1,6-glucosidic bonds" : "number of -1,4-glucosidic bonds") is preferably 1 : 1 to 1 : 1 x 10315 , more preferably 1 : 1.1 to 1 : 500, further preferably 1 : 1.2 to 1 : 100, further more preferably 1 : 1.5 to 1 : 50, and most preferably 1 : 2 to 1 : 20. The ratio may be, in some cases, 1 : 10 to 1 : 5 x 103, 1 : 50 to 1 : 1 x 103, or 1 : 100 to 1 : 500. 20 In the present invention, the lower limit of the branching frequency of the branched glucan is preferably 0.2% or more, preferably 1% or more, more preferably 2% or more, and most preferably 5% or more. While there is no specific upper limit of the branching frequency, it can be, for example, 99% or 25 less, 90% or less, 85% or less, 65% or less, 50% or less, or the like. The branching frequency is calculated by {(number of -1,6-bonds)/(sum of -1,4-bonds and -1,6-bonds in glucan)} x 100.
[0054] The -1,6-glucosidic bonds may be randomly 30 distributed in the -glucan or may be homogeneously distributed in the -glucan. A distribution to such an extent that a linear chain part(s) of 5 or more saccharide units can be formed in the -glucan is preferable. EG038PCT In a particular embodiment, a branched glucan having a large number of non-reducing ends is preferable. The more the number of non-reducing ends in a branched glucan, the binding amount of a saccharide residue such as an N-acetylglucosamine residue, a galactose residue, a manno5 se residue, a glucuronic acid residue, a glucosamine residue, or a xylose residue per one molecule can be increased. The number of non-reducing ends of a branched -1,4 glucan used in the present invention is specifically 2 or more, 3 or 10 more, 5 or more, and is preferably about 10 or more, more preferably about 30 or more, and about 60 or more. The number of non-reducing ends of a branched -glucan is preferably about 1 x 104 or less, more preferably about 5 x 103 or less. A branched glucan having a larger number of non-reducing 15 ends is preferable. Branched CD is not preferable. Since the branched CD has one non-reducing end per one molecule and has a cyclic backbone consisting of an -1,4 glucan having 6 to 8 glucose residues, and is amylase resistant, it is not preferable. 20 [0055] In the present invention, a modified product of the glucan may be used in place of the glucan. Examples of the modified product of the glucan include a modified starch and an esterified product of the glucan explained above. Furthermore, the modified product of the glucan may be a 25 hydroxyl group-modified product or a reducing end-modified product. In addition, as described later, after at least one residue selected from N-acetylglucosamine residue and galactose residue is bound to at least one non-reducing end of the glucan, a glucan moiety may be modified. 30 [0056] The modified starch is a starch which was made to have a nature that it is easier to use by subjecting a natural starch to treatment such as hydrolysis, esterification or gelatinization. Wide variety of modified starches having EG038PCT a variety of combinations of a gelatinization initiation temperature, a viscosity of a starch paste, a degree of transparency of a starch paste, stability against retrogradation and the like are available. There are various types of modified starches. An example 5 mple of such a starch is a starch obtained by immersing starch granules in an acid at a gelatinization temperature or lower of the starch, thereby cutting a starch molecule but not destroying starch granules. 10 [0057] Examples of the modified product of the glucan other than the modified starch include a modified product in which at least one of alcoholic hydroxyl groups of an unmodified glucan is modified (hereinafter, in the present specification, referred to as a "hydroxyl group-modified product of glucan"), 15 a modified product in which some of non-reducing ends of the glucan is modified (hereinafter, in the present specification, referred to as a " non-reducing end-modified product of glucan") and a modified product in which the reducing end of a glucan is modified (hereinafter, in the 20 present specification, referred to as a "reducing end-modified product of glucan").
[0058] Examples of the modification at a hydroxyl group include hydroxyalkylation, alkylation, acylation, carboxymethylation, sulfation and phosphorylation. It is 25 preferable that modification at a hydroxyl group is a modification which can be removed with an enzyme in a body. The hydroxyl group-modified product of the glucan is preferably an acylated glucan, and further preferably an acetylated glucan. The frequency of introduction of the 30 modifying group(s) into alcoholic hydroxyl groups can be arbitrarily set at the time of a modification reaction of the glucan. The frequency of introduction of the modifying group(s) into alcoholic hydroxyl groups is expressed as DS, EG038PCT and DS1 means the state where one modifying group per glucose residue is introduced. DS can be calculated by DS = (number of modifying group)/(number of glucose residue). Since there is an OH group at the 2-position, the 3-position and 5 the 6-position in an unmodified glucose residue, theoretically, maximum 3 modifying groups per glucose residue can be introduced. For this reason, the upper limit of DS is usually 3. The frequency of introduction of the modifying group(s) into alcoholic hydroxyl groups is about DS 0.01 10 or more, more preferably about DS 0.03 or more, further preferably about DS 0.05 or more, particularly preferably about DS 0.07 or more, and most preferably about DS 0.1 or more. The frequency of introduction of modifying group(s) is preferably about DS 1.5 or less, more preferably about 15 DS 1.3 or less, further preferably about DS 1.1 or less, particularly preferably about DS 1.0 or less, and most preferably about DS 0.9 or less. By modifying the glucan, degradation of the glucan in blood or in a body is suppressed.
[0059] Examples of modification at a non-reducing end 20 include binding with a targeting molecule such as a mannose residue, a molecule for drug binding such as a glucuronic acid residue and a glucosamine residue, and an antigen-presenting cell stimulating molecule such as a mannose residue and a xylose residue. Modification at a 25 non-reducing end will be explained in detail in the following 2.6 and 3. Non-reducing end modification is preferably modification by binding of a mannose residue, a glucosamine residue, a glucuronic acid residue, or a xylose residue. By binding of a glucosamine residue, an amino group is imparted 30 to a non-reducing end of a glucan. Since an amino group has a positive charge in an aqueous solution, binding by a non-covalent bond with a drug having a negative charge in an aqueous solution becomes possible. In addition, an amino EG038PCT group can also be utilized for binding via a covalent bond with a drug. In addition, by binding of a glucuronic acid residue, a carboxyl group is imparted to a non-reducing end of a glucan. Since a carboxyl group has a negative charge in an aqueous solution, binding by a non-5 -covalent bond with a drug having a positive charge in an aqueous solution becomes possible. In addition, carboxyl group can also be utilized for binding via a covalent bond with a drug. In a particular embodiment, none of a glucosamine residue and a glucuronic 10 acid residue is bound in the non-reducing end-modified product of the present invention.
[0060] In modification of a non-reducing end, it is preferable that a saccharide residue such as a mannose residue or a galactose residue, which activates an antigen-presenting 15 cell such as a dendritic cell or a macrophage, is bound. It is preferable that at least two or more of an N-acetylglucosamine residue(s) and a galactose residue(s) are bound to a non-reducing end(s) of a glucan. Further, it is more preferable that two or more kinds of monosaccharide 20 residues that are not only an N-acetylglucosamine residue or a galactose residue, but also include a mannose residue, a glucuronic acid residue, a glucosamine residue, or a xylose residue are bound.
[0061] Examples of modification at a reducing end include 25 binding with a substance selected from the group consisting of a monosaccharide, a non-reducing carbohydrate, a biocompatible macromolecule, a liposome constituent component, a glycoside and an amine group-containing low-molecular weight substance. Modification at a 30 non-reducing end will be explained in detail in the following 2.6 and 3 sections.
[0062] (1.2) Acetylglucosamine or galactose Acetylglucosamine has the same meaning as EG038PCT N-acetylglucosamine, and is indicated by GlcNAc. Acetylglucosamine is a substance in which an OH group at a 2-position of glucose is substituted with a NHCOCH3 group.
[0063] Galactose is an epimer of D-glucose, and is a substance in which 5 h configurations of an OH group and an H group at a 4-position of glucose are interchanged. Since galactose is recognized by an asialoglycoprotein receptor present on a hepatic parenchymal cell surface, it is particularly effective in the present invention. 10 [0064] In the method of the present invention, acetylglucosamine-1-phosphate or galactose-1-phosphate is used. Acetylglucosamine-1-phosphate or galactose-1-phosphate may be commercially available one, or may be synthesized by a chemical method, an enzymatic 15 method or a biological method such as fermentation. Acetylglucosamine or galactose may be used for synthesizing acetylglucosamine-1-phosphate or galactose-1-phosphate.
[0065] (1.3) Other monosaccharides In the present invention, monosaccharide-1-phosphates 20 other than acetylglucosamine-1-phosphate or galactose-1-phosphate can be used. Examples of such a monosaccharide-1-phosphate include mannose-1-phosphate, glucuronic acid-1-phosphate, glucosamine-1-phosphate and xylose-1-phosphate. In order to obtain a glucan having the 25 cell stimulating activity, among these monosaccharide-1-phosphates, particularly, mannose-1-phosphate, glucuronic acid-1-phosphate and xylose-1-phosphate are preferable. These monosaccharide-1-phosphates can be used in random 30 combination with acetylglucosamine-1-phosphate and galactose-1-phosphate. As these monosaccharide-1-phosphates, commercially available ones may be used, or chemically synthesized or enzymatically EG038PCT synthesized ones according to the methods known in the art may be used.
[0066] (2. Method for producing a glucan in which at least one residue selected from N-acetylglucosamine residue and galactose residue is bound via an -1,4 bond to 5 non-reducing end) (2.1) Acetylglucosamine-1-phosphate or galactose-1-phosphate As acetylglucosamine-1-phosphate or 10 galactose-1-phosphate utilized in the present invention, those synthesized by a chemical method, an enzymatic method, or a biological method such as fermentation can be used. As an example of a method of synthesizing acetylglucosamine-1-phosphate, for example, an enzymatic 15 method is disclosed in Japanese Laid-Open Publication No. 2007-97517. As an example of a method of synthesizing galactose-1-phosphate, for example, an enzymatic method is disclosed in Manu R. M. De Groeve et al., Biotechnol. Lett. 2009, 31, 1873-1877. 20 [0067] As acetylglucosamine-1-phospate, either of acetylglucosamine-1-phospate in a non-salt form and acetylglucosamine-1-phospate in a salt form can be used. For example, a metal salt of acetylglucosamine-1-phospate can be used, and an alkali metal salt of 25 acetylglucosamine-1-phospate (e.g. disodium acetylglucosamine-1-phosphate and dipotassium acetylglucosamine-1-phosphate) can be used.
[0068] As galactose-1-phospate, either of galactose-1-phospate in a non-salt form and 30 galactose-1-phospate in a salt form can be used. For example, a metal salt of galactose-1-phospate can be used, and an alkali metal salt of galactose-1-phospate (e.g. disodium galactose-1-phospate and dipotassium galactose-1-phospate) EG038PCT can be used.
[0069] (2.2) -Glucan phosphorylase In the present specification, the term "-glucan phosphorylase" means an enzymes having -glucan phosphorylase activity. 5 -Glucan phosphorylase is classified in EC 2.4.1.1. -Glucan phosphorylase activity refers to an activity catalyzing a reaction producing glucose-1-phosphate and partial degraded products of an -1,4-glucan from inorganic phosphate and the -1,4-glucan, 10 or the reverse reaction thereof. -Glucan phosphorylase can also catalyze an -1,4-glucan synthesizing reaction which is the reverse reaction relative to phosphorolysis. In which direction a reaction proceeds depends on the amount of substrate. 15 [0070] In the present invention, any -glucan phosphorylase can be used as long as it has a function to transfer a desired residue (e.g. an N-acetylglucosamine residue, when it is intended that an N-acetylglucosamine residue is bound to a glucan; or a galactose residue, when it is intended that 20 a galactose residue is bound to a glucan) to a non-reducing end of glucan. -glucan phosphorylase used in the present invention can be derived from a bacterium, a yeast, an animal or a plant. -glucan phosphorylase of the present invention can be derived from, for example, potato, sweet potato, Fava 25 bean, Arabidopsis thaliana, spinach, corn, rice, wheat, Citrus hybrid cultivar, Aquifex aeolicus, Thermotoga maritima, Thermococcus zilligii, Thermoanaerobacter pseudethanolicus, or the like.
[0071] It is preferable that -glucan phosphorylase used 30 in the present invention is -glucan phosphorylase derived from Aquifex aeolicus VF5, potato-derived -glucan phosphorylase or Thermococcus zilligii AN1-derived -glucan phosphorylase, and more preferably it is -glucan EG038PCT phosphorylase derived from Aquifex aeolicus VF5. Since -glucan phosphorylase derived from Aquifex aeolicus VF5 have high transferring efficiency, it is quite preferable.
[0072] The base sequence of -glucan phosphorylases derived from Aquifex aeolicus VF5 is set forth 5 rth in SEQ ID NO: 1, and its amino acid sequence is set forth in positions 1-692 of SEQ ID NO: 2. The amino acid sequence of -glucan phosphorylases derived from Aquifex aeolicus VF5 has about 21% to about 24 % sequence identity with the amino acid sequence 10 of plant -glucan phosphorylases, about 34% sequence identity with the amino acid sequence of -glucan phosphorylases derived from Thermus thermophilus, and about 38% sequence identity with the amino acid sequence of -glucan phosphorylases derived from Thermococcus litoralis. It has 15 about 38% sequence identity with the amino acid sequence of -glucan phosphorylases derived from Thermotoga maritima, about 38% sequence identity with the amino acid sequence of maltodextrin phosphorylases derived from Thermococcus zilligii AN1, and about 33% sequence identity with those 20 of Thermoanaerobacter pseudethanolicus.
[0073] The base sequence of type L -glucan phosphorylases derived from potato is set forth in SEQ ID NO: 3, and its amino acid sequence is set forth in positions 15-930 of SEQ ID NO: 4. The base sequence of -glucan phosphorylases 25 derived from Thermococcus zilligii AN1 is set forth in SEQ ID NO: 5, and its amino acid sequence is set forth in positions 1-717 of SEQ ID NO: 6.
[0074] In the present specification, an enzyme "derived from" an organism, means not only that the enzyme is directly 30 isolated from the organism, but also refers to an enzyme obtained by utilizing the organism in any form. For example, when a gene encoding an enzyme obtained from an organism is introduced into Escherichia coli, and the enzyme is EG038PCT isolated from that Escherichia coli, the enzyme is referred to as being "derived from" the organism.
[0075] In the present specification, "identity" of a sequence (for example, an amino acid sequence, a base sequence and the like) refers to the degree of 5 occurrence of the same amino acid (base when base sequences are compared) between two sequences. Identity can be generally determined by comparing two amino acid sequences or two base sequences, and comparing these two sequences which are aligned in an 10 optimal format, which can contain additions or deletions.
[0076] In the present specification, the identity of sequences is calculated using maximum matching of GENETYX-WIN Ver.4.0 (Genetics Co., Ltd.). This program aligns sequence data to be analyzed, and sequence data to be compared so 15 that amino acid pairs matched between sequences become greatest while substitution and deletion are considered, and thereupon, gives a score to each of Matches, Mismatches, and Gaps, calculates a sum, outputs alignment at the smallest sum, and calculates identity thereupon (Reference: Takeishi, 20 K., and Gotoh, O. 1984. Sequence Relationships among Various 4.5 S RNA Species J. Biochem. 92:1173-1177).
[0077] For example, the amino acid sequence of -glucan phosphorylases used in the present invention can be same with SEQ ID NO: 2, 4 or 6, i.e., it can have 100% identity. 25 In another embodiment, as long as having activity to transfer a intended residue (i.e., an acetylglucosamine residue, when it is intended that an acetylglucosamine residue is transferred; or a galactose residue, when it is intended that a galactose residue is transferred) to non-reducing 30 end of a glucan to form an -1,4 bond, this amino acid sequence may be altered in up to a certain number of amino acids compared with a reference amino acid sequence. Such alterations can be selected from the group consisting of a deletion, a EG038PCT substitution (including conservative substitution and non-conservative substitution), or an insertion of at least 1 (for example, 1 or several) amino acids. This alteration may occur at a position of an amino terminus or a carboxyl terminus of the amino acid sequence of SEQ ID NO: 2, 5 4 or 6, or may occur at any position other than these termini. Alteration of an amino acid residue may be interspersed with one residue, or a few residues may be contiguous. For example, -glucan phosphorylases used in the present invention may 10 be added with amino acid residues (preferably about 20 or less residues, more preferably about 10 or less residues, and further preferably about 5 or less residues) at either terminus of the amino acid sequence of SEQ ID NO: 2, 4 or 6, for the reasons such as to make ease of purification of 15 the enzyme, to increase stability, or the like.
[0078] The -glucan phosphorylase used in the present invention has an amino acid sequence which has preferably about 50% or more, more preferably about 60% or more, further more preferably about 70% or more, still more preferably 20 about 80% or more, particularly more preferably about 90% or more, and most preferably about 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 2, 4 or 6 and has an activity transferring a intended residue (i.e., an acetylglucosamine residue, when it is intended 25 that an acetylglucosamine residue is transferred; or a galactose residue, when it is intended that a galactose residue is transferred) to a non-reducing end of the glucan to form an -1,4 bond. The -glucan phosphorylase used in the present invention can have an amino acid sequence which 30 has about 96 % or more, about 97% or more, about 98 % or more, or about 99 % more sequence identity with amino acid sequence of SEQ ID NO: 2, 4 or 6.
[0079] The amount of the -glucan phosphorylase contained EG038PCT in a solution at the start of the reaction is preferably about 0.01 U/ml or more, more preferably about 0.1 U/ml or more, particularly preferably about 0.5 U/ml or more, and most preferably about 1 U/ml or more. The amount of the -glucan phosphorylase contained in 5 a solution at the start of the reaction is preferably about 1,000 U/ml or less, more preferably about 100 U/ml or less, particularly preferably about 50 U/ml or less, and most preferably about 20 U/ml or less. If the weight of -glucan phosphorylase is too large, 10 it may became easy to aggregate the enzyme denatured during the reaction. If the amount used is too small, reaction itself occurred, but the yield of glucan may be lowered. It is noted that unit amount of -glucan phosphorylase is defined as follows: 15 Regarding one unit of -glucan phosphorylase, an -glucan phosphorylase activity which produces 1 mol inorganic phosphate (Pi) per one minute shall be one unit (U or Unit). This measurement of -glucan phosphorylase activity quantitates free inorganic phosphate (Pi) produced from G-1-P. 20 After 200 l of a reaction solution (containing 12.5 mM G-1-P, 1% dextrin and an enzyme solution in a 100 mM acetate buffer (pH 6.0)) is incubated at 50°C for 15 minutes, 800 l of a molybdenum regent (15 mM ammonium molybdate, 100 mM zinc acetate) is added, and this is stirred to stop the reaction. 25 200 l of 568 mM ascorbic acid (pH 5.8) is added, followed by mixing. After incubation at 30°C for 15 minutes, an absorbance is measured at 850 nm using a spectrophotometer. An absorbance is measured similarly using inorganic phosphate having the known concentration, and a standard curve is 30 produced. An absorbance value obtained for a sample is fitted to this standard curve, and the amount of inorganic phosphate in the sample is determined. Inorganic phosphate is quantitated as a phosphoric acid ion. The amount of EG038PCT glucose-1-phosphate is not quantitated.
[0080] (2.3 Production of -glucan phosphorylase) -Glucan phosphorylase used in the present invention can be directly isolated from an organism producing -glucan phosphorylase, such as the aforementioned organisms, 5 present in the natural world. Alternatively, -glucan phosphorylase used in the present invention may be isolated from a microorganism (for example, bacteria, fungi and the like) which has been genetically modified with a gene encoding 10 -glucan phosphorylase isolated from the aforementioned organism.
[0081] In a preferable embodiment, -glucan phosphorylase derived from Aquifex aeolicus VF5 is produced by chemically synthesizing a gene fragment of SEQ ID NO: 1, constructing 15 an expression vector containing this gene fragment, introducing this expression vector into a microorganism to make a recombinant microorganism, culturing this recombinant microorganism to produce -glucan phosphorylase, and collecting produced -glucan phosphorylase. -glucan 20 phosphorylase derived from other organism can also be produced as well. An enzymatic production method by gene recombination is well-known to those skilled in the art. A host microorganism used in the present invention includes a prokaryote and a eukaryote, and a mesophile is preferable. 25 Examples of a particularly preferable microorganism include, but not limited to, Escherichia coli.
[0082] -glucan phosphorylase having the amino acid sequence of positions 1-692 of SEQ ID NO: 2, positions 15-930 of SEQ ID NO: 4, or positions 1-717 of SEQ ID NO: 6, or an 30 amino acid sequence having homology thereto and having an activity transferring an N-acetylglucosamine, galactose, mannose, glucuronic acid, glucosamine or xylose residue, and a polynucleotide encoding the -glucan phosphorylase EG038PCT which are used in the present invention can be produced using conventional genetic engineering techniques.
[0083] (2.4) Production of a glucan containing acetylglucosamine residue(s) or galactose residue(s) The 5 glucan containing an acetylglucosamine residue(s) or galactose residue(s) of the present invention can be produced by a method including a step of allowing a reaction of a solution containing acetylglucosamine-1-phosphate or galactose-1-phosphate, a glucan, and -glucan phosphorylase 10 (for example, -glucan phosphorylase derived from Aquifex aeolicus VF5, -glucan phosphorylase derived from potato, or -glucan phosphorylase derived from Thermococcus zilligii AN1) which can catalyze a reaction of transferring an acetylglucosamine residue or a galactose residue to a 15 non-reducing end of a glucan. By using a glucan modified product in place of a glucan in this method, a modified product of the glucan containing acetylglucosamine residue(s) or galactose residue(s) can be produced. As an example, a method using a glucan will be explained below. 20 [0084] First, a reaction solution is prepared. The reaction solution can be prepared, for example, by adding acetylglucosamine-1-phosphate or galactose-1-phosphate, a glucan, and -glucan phosphorylase to a suitable solvent. Either one of acetylglucosamine-1-phosphate and 25 galactose-1-phosphate may be used, or both of acetylglucosamine-1-phosphate or galactose-1-phosphate may be used simultaneously. If necessary, any buffer and inorganic salts for the purpose of adjusting the pH, as far as an enzymatic reaction is not inhibited, may be added to 30 this reaction solution. If necessary, glucose-1-phosphate which is an original substrate of -glucan phosphorylase may be added to this reaction solution. In the case of a reaction where acetylglucosamine-1-phosphate or EG038PCT galactose-1-phosphate and glucose-1-phosphate are coexistent, a reaction of binding a glucose residue to a non-reducing end of a receptor glucan and a reaction of binding acetylglucosamine residue or galactose residue are simultaneously performed. If an acetylglucosamine 5 etylglucosamine residue or a galactose residue is bound to a non-reducing end of the glucan, -glucan phosphorylase can further transfer a molecule to the non-reducing end of the acetylglucosamine residue or the galactose residue, however, the efficiency 10 of the transfer is much lower than the efficiency of transferring to a glucose residue. However, when a glucose residue is bound to a non-reducing end of a glucan, -glucan phosphorylase can further transfer a glucose residue or an acetylglucosamine residue or galactose residue to a 15 non-reducing end of a resulting molecule. For this reason, when glucose-1-phosphate is coexistent, the chain length of the glucan can be extended efficiently. Therefore, the structure of the finally obtained non-reducing end-modified glucan is controlled by a ratio between added 20 acetylglucosamine-1-phosphate or galactose-1-phosphate and added glucose-1-phosphate. If necessary, an enzyme selected from the group consisting of a debranching enzyme, a branching enzyme, 4--glucanotransferase and a glycogen debranching enzyme may be added to this reaction solution. 25 [0085] By changing the ratio, in a reaction solution, of the amount of acetylglucosamine-1-phosphate or galactose-1-phosphate and the number as a population of non-reducing ends of a glucan, frequency of introduction of acetylglucosamine residue or galactose residue can be 30 controlled. That is, as increasing (number of molecule of glucan) x (amount of acetylglucosamine-1-phosphate or galactose-1-phosphate relative to number of non-reducing ends in the molecule), the frequency of introduction of EG038PCT acetylglucosamine residue or galactose residue can be increased. In addition, also by regulating the amount of enzyme added or enzyme reaction time, the frequency of introduction of acetylglucosamine residue or galactose 5 residue can be regulated.
[0086] When non-reducing end modification of a glucan is performed with two or more kinds of saccharide residues, a reaction may be performed by adding two or more kinds of saccharide-1-phospates, in one kind of them or mixed in the 10 same reaction liquid. For example, desired saccharide-1-phosphate selected from N-acetylglucosamine-1-phosphate, galactose-1-phosphate, glucuronic acid-1-phosphate, glucosamine-1-phosphate, mannose-1-phosphate, and xylose-1-phosphate may be reacted 15 one kind by one kind. Alternatively, two or more kinds of them may be reacted simultaneously. For example, when it is desired that a saccharide residue selected from a glucuronic acid residue, a glucosamine residue, a mannose residue and a xylose residue is further bound, glucuronic 20 acid-1-phosphate, glucosamine-1-phosphate, mannose-1-phosphate, and xylose-1-phosphate are reacted in one kind of them or a combination of them, with a non-reducing end of a branched glucan.
[0087] Then, the reaction solution is reacted, if necessary, 25 by heating by a method known in the art. The reaction temperature can be any temperature, as far as the effect of the present invention is obtained. The reaction temperature can be representatively a temperature of about 30oC to about 90oC. It is preferable that the temperature 30 of a solution in this reaction step is such a temperature that, after a predetermined reaction time, about 50% or more, more preferably about 80% or more activity of the activity of the -glucan phosphorylase contained in this solution EG038PCT before the reaction remains. The reaction temperature is preferably about 35oC to about 80oC, more preferably about 35oC to about 70oC, and further preferably about 35oC to about 65oC. -Glucan phosphorylase derived from Aquifex aeolicus VF5 is a thermostable 5 table enzyme, and its optimal reaction temperature is about 80oC to 90oC. From the viewpoint of the reaction speed, it is preferable that the reaction temperature is high to some extent. On the other hand, from the viewpoint of the optimal reaction temperature of -glucan 10 phosphorylase derived from Aquifex aeolicus VF5, a reaction at about 80oC to 90oC is possible. However, from the viewpoint of stability of the resulting product, stability of acetylglucosamine-1-phosphate or galactose-1-phosphate and glucose-1-phosphate, and the like, it is preferable that 15 the reaction temperature is slightly lower than the optimal reaction temperature of the -glucan phosphorylase derived from Aquifex aeolicus VF5. The reaction temperature is preferably about 30oC or higher, more preferably about 35oC or higher, further preferably about 40oC or higher. In a 20 particular embodiment, the reaction temperature may be about 45oC or higher or about 50oC or higher. The reaction temperature is preferably about 90oC or lower, more preferably about 80oC or lower, further preferably about 70oC or lower. In a particular embodiment, the reaction temperature may be about 65oC or lower or about 60o25 C or lower. In the case where an enzyme for which an optimum reaction temperature is lower such as potato-derived -glucan phosphorylase is used, it is preferable that the reaction temperature is set lower than the case where Aquifex aeolicus VF5-derived 30 -glucan phosphorylase is used.
[0088] The reaction time can be set in any time period, in view of the reaction temperature and remaining activity of an enzyme. The reaction time is representatively about 1 EG038PCT hour to about 100 hours, more preferably about 1 hour to about 72 hours, further more preferably about 2 hours to about 36 hours, and most preferably about 2 hours to about 24 hours. In a particular embodiment, the reaction time may 5 be, for example, about 1 hour or longer, about 2 hours or longer, about 5 hours or longer, about 10 hours or longer, about 12 hours or longer, or about 24 hours or longer. In a particular embodiment, the reaction time may be, for example, about 100 hours or shorter, about 72 hours or shorter, about 10 60 hours or shorter, about 48 hours or shorter, about 36 hours or shorter, or about 24 hours or shorter.
[0089] Heating may be performed using any means, but it is preferable that heating is performed with stirring so as to homogeneously transmit the heat to the whole solution. 15 The solution is stirred by placing it into, for example, a reaction tank made of stainless steel, provided with a warm water jacket and a stirring device.
[0090] Furthermore, in the method of the present invention, at least one of acetylglucosamine-1-phosphate or 20 galactose-1-phosphate , a glucan, and -glucan phosphorylase may be further added to a reaction solution at a stage where the reaction has proceeded to some extent.
[0091] In this way, a solution containing a non-reducing end-modified glucan is produced. 25 [0092] After completion of the reaction, in the reaction solution, if necessary, an enzyme in the reaction solution can be inactivated by, for example, heating at 100oC for 10 minutes. After completion of the reaction, enzyme may be removed by making pH of the reaction solution to be acidic 30 to denature the enzyme protein. Alternatively, a post step may be performed without performing treatment of inactivating an enzyme. The reaction solution may be stored as it is, or may be treated in order to isolate the produced non-reducing EG038PCT end-modified glucan.
[0093] After completion of the reaction, after the non-reducing end-modified glucan is purified, or before the non-reducing end-modified glucan is purified, a hydroxyl group-5 modified product of the non-reducing end-modified glucan may be produced by modifying at least one of alcoholic hydroxyl groups of a glucan moiety of the resulting non-reducing end-modified glucan. It is preferable that modification is performed after purification of the 10 non-reducing end-modified glucan. Modification can be performed according to a method known in the art. Examples of modification include hydroxyalkylation, alkylation, acylation, carboxymethylation, sulfation, and phosphorylation. Acylation is preferable, and acetylation 15 is more preferable. By modifying a reducing end of the glucan after producing the glucan containing N-acetylglucosamine residue(s) or galactose residue(s) or a hydroxyl group-modified product of the glucan containing N-acetylglucosamine residue(s) or galactose residue(s), a 20 reducing end-modified product of the glucan containing N-acetylglucosamine residue(s) or galactose residue(s) or a hydroxyl group-modified product of the glucan containing N-acetylglucosamine residue(s) or galactose residue(s) may be produced. Further, a non-reducing end of these glucan 25 moiety to which neither N-acetylglucosamine residue nor galactose residue is bound, may be modified. Binding of an acetylglucosamine residue or galactose residue to the glucan, modification of a hydroxyl group, modification of a reducing end, and modification of some of non-reducing ends with a 30 modifying group other than an N-acetylglucosamine residue or galactose residue may be performed in any order.
[0094] (2.5 Purification of a glucan in which at least one residue selected from an N-acetylglucosamine residue or an EG038PCT galactose residue is liked via -1,4 bond to the non-reducing end(s))
The produced non-reducing end-modified glucan (or a modified product thereof) can be purified as nec5 essary. Examples of the impurities removed by purification include inorganic phosphate, N-acetylglucosamine-1-phosphate or galactose-1-phosphate, inorganic salts and the like. Examples of a method of purifying a glucan include a method 10 using an organic solvent (T. J. Schoch et al., J. American Chemical Society, 64, 2957 (1942)) and a method not using an organic solvent.
[0095] Examples of the organic solvent which can be used in purification using the organic solvent include acetone, 15 n-amyl alcohol, pentazole, n-propyl alcohol, n-hexyl alcohol, 2-ethyl-1-butanol, 2-ethyl-1-hexanol, lauryl alcohol, cyclohexanol, n-butyl alcohol, 3-pentanol, 4-methyl-2-pentanol, d,l-borneol, -terpineol, isobutyl alcohol, sec-butyl alcohol, 2-methyl-1-butanol, isoamyl 20 alcohol, tert-amyl alcohol, menthol, methanol, ethanol and ether.
[0096] As an example of the purification method not using an organic solvent, there is a method of removing inorganic phosphate, acetylglucosamine-1-phosphate or 25 galactose-1-phosphate, and inorganic salts by subjecting a non-reducing end-modified glucan to membrane fractionation using an ultrafiltration membrane or chromatography, without precipitating the non-reducing end-modified glucan dissolved in water, after the non-reducing end-modified 30 glucan production reaction.
[0097] Examples of the ultrafiltration membrane which can be used in purification include an ultrafiltration membrane of a molecular weight cut off of about 1 x 103 to about 1 EG038PCT x 104, preferably about 5 x 103 to about 5 x 104, more preferably about 1 x 104 to about 3 x 104 (UF membrane unit manufactured by DAICEL).
[0098] Examples of a support which can be used in 5 chromatography include a support for gel filtration chromatography, a support for ligand exchange chromatography, a support for ion-exchange chromatography and a support for hydrophobic chromatography.
[0099] (2.6) Glucan in which at least one residue selected 10 from N-acetylglucosamine residue and galactose residue is bound via -1,4 bond to non-reducing end(s), and modified product thereof. The glucan of the present invention is a glucan in which at least one residue selected from an N-acetylglucosamine 15 residue and a galactose residue is bound via -1,4 bond to each of at least one non-reducing end of a glucan. The glucan of the present invention is also referred to as the non-reducing end-modified glucan of the present invention. The glucan-modified product of the present invention can 20 be a hydroxyl group-modified product of the non-reducing end-modified glucan, or a further non-reducing end-modified product or reducing end-modified product of the present invention. The non-reducing end-modified glucan of the present 25 invention is a glucan in which at least one residue selected from an N-acetylglucosamine residue and a galactose residue is bound via -1,4 bond to each of at least one non-reducing end of a glucan. To an end of an N-acetylglucosamine residue or a galactose residue bound to a non-reducing end of this 30 glucan may be further bound a saccharide or the like, if necessary. When two or more of an N-acetylglucosamine residue or a galactose residue, or a combination thereof are bound to one non-reducing end of the non-reducing EG038PCT end-modified glucan of the present invention, a structure is that these monosaccharides are bound and bind to one end. For example, the structure is that wherein one monosaccharide residue is bound to one non-reducing end of a glucan, and the next monosaccharide residue 5 is further bound to the non-reducing end of the monosaccharide residue. In one embodiment, only one monosaccharide residue is bound to each end of non-reducing ends of a glucan.
[0100] In the non-reducing end-modified glucan of the 10 present invention, N-acetylglucosamine residue(s) or galactose residue(s) or combination thereof may be bound to all of the non-reducing ends of glucan, or these monosaccharide residue(s) may be bound to only a part of the non-reducing ends. That is, some of the non-reducing 15 ends can remain unbound by these monosaccharide residues.
[0101] Conversion ratio based on the number of non-reducing end(s), that is, the ratio of the number of bond(s) between monosaccharide(s) selected from N-acetylglucosamine residue(s) or galactose residue(s) or combination thereof 20 and non-reducing end(s) relative to the number of non-reducing end(s) present before these monosaccharide(s) is/are bound, can be selected as appropriate depending on the application wherein the glucan containing either of these monosaccharide residues is used or the like, from the ratio 25 close proximity of 0% (for example, about 1%) to 100%. For example, when it is desired that a small amount of N-acetylglucosamine residue(s) or galactose residue(s) be present, a low conversion ratio can be selected, and when it is desired that a large amount of N-acetylglucosamine 30 residue(s) or galactose residue(s) be present, a high conversion ratio can be selected.
[0102] By appropriately adjusting the condition of the enzymatic reaction in producing a non-reducing end-modified EG038PCT glucan, for example, by adjusting the reaction time, the concentration of the substrate or the like of the enzymatic reaction, a non-reducing end-modified glucan having a selected conversion ratio can easily be obtained. 5 [0103] Further, the ratio of the total number of N-acetylglucosamine residue(s) or galactose residue(s) bound to non-reducing end(s) relative to the number of non-reducing end(s) present in a glucan before these monosaccharide residues(s) is/are bound can be used as an 10 indicator for the amount of these monosaccharides. In the present specification, this ratio is described as binding ratio. In general, in analyzing a non-reducing end-modified glucan of the present invention, it is easier to measure the binding ratio than to measure the above-mentioned 15 conversion ratio, therefore, it is advantageous from the practical viewpoint to design a non-reducing end-modified glucan based on binding ratio.
[0104] It is noted that depending on the condition of enzymatic reaction in synthesizing a non-reducing 20 end-modified glucan, to the end of either of these monosaccharide residues bound to one non-reducing end, either of these monosaccharide residues may be further bound in some cases. That is, in some cases, the structure may be that wherein two these monosaccharides are serially bound 25 to one non-reducing end (that is, a structure wherein a disaccharide is bound to a non-reducing end). A compound having such a structure can also be used as the non-reducing end-modified glucan of the present invention. The above-mentioned binding ratio has an advantage that the 30 amount of N-acetylglucosamine residue(s) or galactose residue(s) can be evaluated even if the amount of N-acetylglucosamine residue(s) or galactose residue(s) is increased by binding a plurality of these monosaccharide EG038PCT residues to one non-reducing end as described above. For this reason, in contrast to the above-mentioned conversion ratio, the binding ratio may have a value greater than 100% in some cases. The binding ratio can be selected as 5 appropriate depending on the application wherein the non-reducing end-modified glucan is used or the like. For example, when it is desired that a small amount of N-acetylglucosamine residue(s) or galactose residue(s) be present, a low binding ratio (for example, about 1% to about 10 2%) can be selected, and when it is desired that a large amount of N-acetylglucosamine residue(s) or galactose residue(s) be present, a high binding ratio (for example, bout 80% to about 120%) can be selected.
[0105] When the application of the non-reducing 15 end-modified branched glucan is a nanoparticulate carrier for a DDS, a total of the binding ratios of the N-acetylglucosamine residues and galactose residues is preferably about 2% or more, more preferably about 5% or more, further preferably about 10% or more, and most 20 preferably about 15% or more; the total of the binding ratios of the N-acetylglucosamine residues and the galactose residues is preferably about 200% or less, more preferably about 150% or less, further preferably about 120% or less, and most preferably about 100% or less. 25 [0106] When the application of the non-reducing end-modified branched glucan is an antigen-presenting cell stimulating molecule, the binding ratio of the N-acetylglucosamine residues or galactose residues is, in a total of them, preferably about 5% or more, more preferably 30 about 10% or more, further preferably about 15% or more, and most preferably about 20% or more; the binding ratio of the N-acetylglucosamine residues or galactose residues is, in a total of them, preferably about 200% or less, more EG038PCT preferably about 150% or less, further preferably about 120% or less, and most preferably about 100% or less.
[0107] When the application of the non-reducing end-modified branched glucan is a DDS carrier, the number of bonds of the N-acetylglucosamine residues or the ga5 lactose residues per glucan molecule is, in a total of them, preferably about 2 or more, more preferably about 5 or more, further preferably about 10 or more, particularly preferably about 20 or more, and most preferably about 50 or more. The number 10 of bonds of the N-acetylglucosamine residues or the galactose residues per glucan molecule is, in a total of them, preferably about 5000 or less, more preferably about 4000 or less, further preferably about 3000 or less, and most preferably about 2000 or less. 15 [0108] When the application of the non-reducing end-modified branched glucan is an antigen-presenting cell stimulating molecule, the number of bonds of the N-acetylglucosamine residues or the galactose residues per glucan molecule is, in a total of them, preferably about 20 2 or more, more preferably about 4 or more, further preferably about 8 or more, particularly preferably about 10 or more, and most preferably about 15 or more. The number of bonds of the N-acetylglucosamine residues or the galactose residues per glucan molecule is, in a total of them, preferably about 25 2000 or less, more preferably about 1000 or less, further preferably about 500 or less, and most preferably about 200 or less.
[0109] In the non-reducing end-modified glucan of the present invention, a sugar residue other than 30 N-acetylglucosamine residue or galactose residue may be bound to the non-reducing end to which neither N-acetylglucosamine residue nor galactose residue is bound. That is, some of non-reducing ends may bind with an N-acetylglucosamine EG038PCT residue or galactose residue, and the remaining non-reducing end(s) may bind with a sugar residue other than these monosaccharides.
[0110] Alternatively, it is also possible to make a structure wherein some of non-reducing ends bind 5 to N-acetylglucosamine residue(s) or galactose residue(s), some bind to a sugar residue other than these monosaccharide, and the remaining non-reducing end(s) bind to nothing. In this regard, it is possible that among a plurality of non-reducing ends, the 10 number of end(s) binding to N-acetylglucosamine residue(s) or galactose residue(s), the number of end(s) binding to a sugar residue other than these monosaccharides, and the number of end(s) not binding to a sugar be selected freely.
[0111] In a particular embodiment of the present invention, 15 a saccharide residue bound to a non-reducing end is an N-acetylglucosamine residue, a galactose residue or a residue of an oligomer (e.g. a dimer) of one kind of them or a combination of them.
[0112] The hydroxyl group-modified product is as described 20 above.
CLAIMS Claim 1. A branched glucan, wherein the branched glucan has a plurality of 5 non-reducing ends, and at least one residue selected from an N-acetylglucosamine residue and a galactose residue is bound via an -1,4-bond to each of two or more non-reducing ends of the branched -1,4-glucan, 10 but neither an N-acetylglucosamine residue nor a galactose residue is present at the position other than the non-reducing ends of the branched -1,4-glucan, and the degree of polymerization of the branched -1,4-glucan is 15 or more and 4 x 105 or less. 15 Claim 2. The branched glucan according to claim 1, wherein the branched -1,4-glucan is selected from the group consisting of a branched maltooligosaccharide, starch, amylopectin, glycogen, dextrin, enzymatically synthesized 20 branched glucan and highly branched cyclic glucan. Claim 3. A hydroxyl group-modified product of the branched glucan according to claim 1, wherein the modification on the hydroxyl group is a modification on some or all of alcoholic 25 hydroxyl groups of the glucan, and the modification on the hydroxyl group is independently selected from the group consisting of hydroxyalkylation, alkylation, acetylation, carboxymethylation, sulfation and phosphorylation. 30 Claim 4. A reducing end-modified product of the branched glucan according to claim 1 or a hydroxyl group-modified product thereof. EG038PCT Claim 5. A non-reducing end-modified product of the branched glucan according to claim 1 or a hydroxyl group-modified product thereof, or a reducing end-modified product thereof, which is further modified by liking a monosaccharide residue other than an N-acetylglucosamine residue and a galactos5 e residue via an -1,4-bond to at least one non-reducing end of the plurality of non-reducing ends of the branched -1,4 glucan. 10 Claim 6. The non-reducing end-modified product of the branched glucan or a hydroxyl group-modified product thereof, or a reducing end-modified product thereof according to claim 5, wherein the monosaccharide residue is one kind or two or more kinds selected from a glucuronic acid residue, a 15 glucosamine residue, a mannose residue, and a xylose residue. Claim 7. The non-reducing end-modified product of the branched glucan or a hydroxyl group-modified product thereof, or a reducing end-modified product thereof according to claim 20 5, wherein the monosaccharide residue is one kind or two or more kinds selected from a glucuronic acid residue, a mannose residue, and a xylose residue. Claim 8. A method for producing a branched glucan in which 25 at least one residue selected from an N-acetylglucosamine residue and a galactose residue is bound to each of two or more non-reducing ends, characterized by allowing an -glucan phosphorylase to act on an aqueous solution comprising a branched -1,4-glucan having two or more non-reducing ends 30 and N-acetylglucosamine-1-phosphate or galactose-1-phosphate, wherein the degree of polymerization of the branched -1,4-glucan is 15 or more and 4 x 105 or less. EG038PCT Claim 9. The method according to claim 8, wherein the -glucan phosphorylase has 95% or more sequence identity with the amino acid sequence of -glucan phosphorylase derived from Aquifex aeolicus VF5, and has activity of 5 transferring N-acetylglucosamine residue or galactose residue to a non-reducing end of a glucan to form an -1,4-bond. Claim 10. A medicament comprising: the branched glucan according to claim 1, a hydroxyl 10 group-modified product thereof, or a reducing end-modified product thereof, and a medically effective ingredient. Claim 11. A medicament comprising: 15 a non-reducing end-modified product of the branched glucan according to claim 1 or a hydroxyl group-modified product thereof, or a reducing end-modified product thereof, which is further modified by liking a monosaccharide residue other than an N-acetylglucosamine residue and a galactose 20 residue via an -1,4-bond to at least one non-reducing end of the plurality of non-reducing ends of the branched -1,4 glucan, wherein the monosaccharide residue is one kind or two kinds selected from a glucuronic acid residue, a glucosamine residue, a mannose residue, and a xylose residue; 25 and a medically effective ingredient. Claim 12. The medicament according to claim 10 or 11, wherein the medically effective ingredient is selected from the group 30 consisting of a low-molecular weight organic compound, a protein, a peptide, an antibody, an antibody fragment, a receptor, a receptor fragment, a DNA, an RNA, a siRNA, an miRNA and an RNA aptamer. EG038PCT Claim 13. The medicament according to claim 10 or 11, wherein the medically effective ingredient is an antigen protein or a peptide. Claim 14. A composition for clinical 5 al diagnosis comprising the branched glucan according to claim 1, a hydroxyl group-modified product thereof, or a reducing end-modified product thereof. 10 Claim 15. A composition for clinical diagnosis comprising a non-reducing end-modified product of the branched glucan according to claim 1 or a hydroxyl group-modified product thereof, or a reducing end-modified product thereof, which is further modified by liking a monosaccharide residue other 15 than an N-acetylglucosamine residue and a galactose residue via an -1,4-bond to at least one non-reducing end of the plurality of non-reducing ends of the branched -1,4 glucan, wherein the monosaccharide residue is one kind or two kinds selected from a glucuronic acid residue, a glucosamine 20 residue, a mannose residue, and a xylose residue. Claim 16. A nanoparticulate carrier for a DDS comprising the branched glucan according to claim 1, a hydroxyl group-modified product thereof, or a reducing end-modified 25 product thereof. Claim 17. A nanoparticulate carrier for a DDS comprising a non-reducing end-modified product of the branched glucan according to claim 1 or a hydroxyl group-modified product 30 thereof, or a reducing end-modified product thereof, which is further modified by liking a monosaccharide residue other than an N-acetylglucosamine residue and a galactose residue via an -1,4-bond to at least one non-reducing end of the EG038PCT plurality of non-reducing ends of the branched -1,4 glucan, wherein the monosaccharide residue is one kind or two kinds selected from a glucuronic acid residue, a glucosamine residue, a mannose residue, and a xylose residue. 5 Claim 18. The carrier according to claim 16 or 17, wherein the nanoparticulate carrier for a DDS is selected from the group consisting of a liposome, a virus particle, a macromolecule micelle and a nanogel composed of macromolecule 10 bearing hydrophobic groups. Claim 19. A vaccine adjuvant comprising the branched glucan according to claim 1, a hydroxyl group-modified product thereof, or a reducing end-modified product thereof. 15 Claim 20. The vaccine adjuvant according to claim 19, wherein the branched -1,4 glucan is further modified by liking a monosaccharide residue other than an N-acetylglucosamine residue and a galactose residue via an -1,4-bond to at least 20 one non-reducing end of the plurality of non-reducing ends of the glucan, wherein the monosaccharide residue is one kind or two kinds selected from a glucuronic acid residue and a mannose residue.